Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AEs, agonist, analyze, ANCOVA, BA, batch, Canadian, Chevron, clean, closer, compressed, cybersecurity, destruction, dissemination, doubt, dual, East, ECG, Eighteen, escalate, exceeded, Florida, GIP, hardware, heightened, highlight, HT, input, insulinotropic, JCEM, LSM, Middle, Muscle, myostatin, network, Nglena, nitrogen, nominating, Notably, notification, OPCO, organizational, Page, pattern, penetration, peptide, physiological, polypeptide, prespecified, provisional, radiation, ransomware, serum, signaling, software, Sogroya, specialist, Washington
Removed:
amplified, anterior, backbone, camptothecin, caring, circuit, comparison, conjugate, contingency, discretionary, disposed, Dr, economy, emergency, Eugene, expanding, extinguished, guarantee, inclusive, infection, inhibit, initiating, installment, Kennedy, leasehold, linked, median, pace, polymer, prioritization, reaction, recoverable, reliant, resigning, selectively, separation, shorter, spread, subcontractor, surfaced, topoisomerase, ultradian, undiscounted, updated, vested, worsen, Wuhan
Filing tables
Filing exhibits
Related press release
LUMO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (Nos. 333-266966, 333-239137, and 333-240149) on Form S-3 and (Nos. 333-178032, 333-184880, 333-186020, 333-203350, 333-234644, 333-237590, and 333-259136) on Form S-8 of our report dated March 7, 2024, with respect to the consolidated financial statements of Lumos Pharma, Inc.
/s/ KPMG LLP
Austin, Texas
March 7, 2024